Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith L Knutson

Showing results (41-50 of 147) with videos related to

Pageof 15
Sort By:
Journal of Clinical Immunology|March 21, 2003
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvantDouglas G McNeel, Keith L Knutson, Kathy Schiffman, et al.
Molecular Cancer Therapeutics|October 28, 2003
Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunityMary L Disis, Nathalie Scholler, Amber Dahlin, et al.
Blood|April 4, 2002
Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancersMary L Disis, Kristine Rinn, Keith L Knutson, et al.
Cancer Research|January 21, 2006
Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chainJames A Thompson, Samudra K Dissanayake, Bruce R Ksander, et al.
Gastroenterology|July 7, 2009
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinomaFrank A Sinicrope, Rafaela L Rego, Stephen M Ansell, et al.
Scientific Reports|December 6, 2012
Disparate roles of marrow- and parenchymal cell-derived TLR4 signaling in murine LPS-induced systemic inflammationJustin E Juskewitch, Jeffrey L Platt, Bruce E Knudsen, et al.
Cancer Causes & Control : CCC|March 2, 2011
Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancerKristin L White, David N Rider, Kimberly R Kalli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic miceKeith L Knutson, Yushe Dang, Hailing Lu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2007
Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: dependence on TCR:peptide-MHC interaction, ICAM-1, IL-12, and IFN-gammaSuresh Radhakrishnan, Karla R Wiehagen, Vesna Pulko, et al.
Breast Cancer Research and Treatment|October 8, 2005
Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals"Masoud H Manjili, Hilal Arnouk, Keith L Knutson, et al.
Pageof 15

Showing results (41-50 of 147) with videos related to

Sort By:
Pageof 15
Journal of Clinical Immunology|March 21, 2003
Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvantDouglas G McNeel, Keith L Knutson, Kathy Schiffman, et al.
Molecular Cancer Therapeutics|October 28, 2003
Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunityMary L Disis, Nathalie Scholler, Amber Dahlin, et al.
Blood|April 4, 2002
Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancersMary L Disis, Kristine Rinn, Keith L Knutson, et al.
Cancer Research|January 21, 2006
Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chainJames A Thompson, Samudra K Dissanayake, Bruce R Ksander, et al.
Gastroenterology|July 7, 2009
Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinomaFrank A Sinicrope, Rafaela L Rego, Stephen M Ansell, et al.
Scientific Reports|December 6, 2012
Disparate roles of marrow- and parenchymal cell-derived TLR4 signaling in murine LPS-induced systemic inflammationJustin E Juskewitch, Jeffrey L Platt, Bruce E Knudsen, et al.
Cancer Causes & Control : CCC|March 2, 2011
Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancerKristin L White, David N Rider, Kimberly R Kalli, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 21, 2006
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic miceKeith L Knutson, Yushe Dang, Hailing Lu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2007
Induction of a Th1 response from Th2-polarized T cells by activated dendritic cells: dependence on TCR:peptide-MHC interaction, ICAM-1, IL-12, and IFN-gammaSuresh Radhakrishnan, Karla R Wiehagen, Vesna Pulko, et al.
Breast Cancer Research and Treatment|October 8, 2005
Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals"Masoud H Manjili, Hilal Arnouk, Keith L Knutson, et al.
Pageof 15